Drug Trial Radar · NCT03564509
A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.
Last checked: Nov 20, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
620
Actual
Start
May 14, 2018
Primary completion
Oct 21, 2019
Study completion Jan 8, 2020
Sponsor
- Lead sponsor
- Ferring PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Jun 21, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- Female only, from 30 years, up to 42 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this phase 2 dose-ranging trial is to investigate the effects of FE 999302 on parameters influencing pregnancy rates in women undergoing Controlled Ovarian Stimulation (COS) with follitropin delta in a long gonadotropin releasing hormone (GnRH) agonist protocol. Furthermore, the study intends: * To investigate the safety of FE 999302 in women undergoing COS with follitropin delta in a long GnRH agonist protocol. * To investigate the potential immunogenicity of FE 999302 in subjects undergoing COS with follitropin delta in a long GnRH agonist protocol. * To estimate the impact of body weight on FE 999302 exposure in subjects undergoing COS with follitropin delta in a long GnRH agonist protocol.
Conditions
- Controlled Ovarian Stimulation
Interventions
FE 999302 (1 μg) and follitropin deltaDrug
Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.
FE 999302 (2 μg) and follitropin deltaDrug
Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
FE 999302 (4 μg) and follitropin deltaDrug
Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
FE 999302 (8 μg) and follitropin deltaDrug
Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
FE 999302 (12 μg) and follitropin deltaDrug
Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.
Placebo and follitropin deltaOther
Daily dose of placebo; individualized follitropin delta dose.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of good-quality blastocysts on Day 5 after oocyte retrievalTime frame: On Day 5 after oocyte retrieval
Locations
20 sites in 5 countries. Site status is shown where the registry gives one.
Universitair Ziekenhuis Gent (UZ Gent)
Ghent, Belgium
Universitair Ziekenhuis Brussel
Jette, Belgium
Institut fur Reproduktionsmedizin und Genetik
Karlovy Vary, Czechia
Fertimed
Olomouc, Czechia
GYNEM
Prague, Czechia
IVF CUBE
Prague, Czechia
Aalborg University Hospital
Aalborg, Denmark
Rigshospitalet
Copenhagen, Denmark
Dansk Fertilitetsklinik
Frederiksberg, Denmark
Hvidovre Hospital
Hvidovre, Denmark
Dexeus Woman's Health
Barcelona, Spain
Instituto Valenciano de Infertilidad (IVI) - Bilbao
Leioa, Spain
GINEFIV - Clinica Belen Location
Madrid, Spain
Instituto Valenciano de Infertilidad (IVI) - Madrid
Madrid, Spain
Instituto Valenciano de Infertilidad (IVI) - Sevilla
Seville, Spain
Instituto Valenciano de Infertilidad (IVI) - Valencia
Valencia, Spain
Glasgow Royal Infirmary
Glasgow, United Kingdom
Liverpool Women's Hospital
Liverpool, United Kingdom
Guy's and St Thomas' NHS Trust
London, United Kingdom
Kings College (Assisted Conception Unit)
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.